v.231201
Showing details for project SYSMHC00005
| SampleID |
NumReplicates |
Organism |
TissueType |
CellType |
MHCAllele |
| SampleID |
NumReplicates |
Organism |
TissueType |
CellType |
MHCAllele |
| SYSMHC00005_Fib |
4 |
Human |
|
|
HLA-A03:01,HLA-A23:01,HLA-B08:01,HLA-B15:18,HLA-C07:02,HLA-C07:04 |
| SYSMHC00005_HCC1143 |
3 |
Human |
|
|
HLA-A31:01,HLA-B35:08,HLA-B37:01,HLA-C04:01,HLA-C06:02 |
| SYSMHC00005_HCC1937 |
4 |
Human |
|
|
HLA-A23:01,HLA-A24:02,HLA-B07:02,HLA-B40:01,HLA-C03:04,HLA-C07:02 |
| SYSMHC00005_HCT116 |
4 |
Human |
|
|
HLA-A01:01,HLA-A02:01,HLA-B45:01,HLA-B18:01,HLA-C05:01,HLA-C07:01 |
| SYSMHC00005_JY |
3 |
Human |
|
|
HLA-A02:01,HLA-B07:02,HLA-C07:02 |
| SYSMHC00005_SupB15-RT |
4 |
Human |
|
|
HLA-A03:01,HLA-A11:01,HLA-B51:01,HLA-B52:01,HLA-C12:04,HLA-C14:02 |
| SYSMHC00005_SupB15-WT |
4 |
Human |
|
|
HLA-A03:01,HLA-A11:01,HLA-B51:01,HLA-B52:01,HLA-C12:04,HLA-C14:02 |
Detailed view of sample SYSMHC00005_HCC1143
| ID |
SampleID |
RawFileName |
Organism |
Process |
Tissue Type |
Cell Type |
Culture Conditions |
Disease State |
Comments |
MHCClass |
MHCAllele |
PubMed ID |
Peptide |
Isolation Method |
Antibody |
Mass Spectrometer |
LC System |
iRT Peptides |
Acquisition Mode |
Fragmentation Method |
Gradient |
Gradient Length |
Flow Rate |
Replicate Number |
| ID |
SampleID |
RawFileName |
Organism |
Process |
Tissue_Type |
Cell_Type |
Culture_Conditions |
Disease_State |
Comments |
MHCClass |
MHCAllele |
PubMed_ID |
Peptide |
Isolation_Method |
Antibody |
Mass_Spectrometer |
LC_System |
iRT_Peptides |
Acquisition_Mode |
Fragmentation_Method |
Gradient |
Gradient_Length |
Flow_Rate |
Replicate_Number |
| SYSMHC00005 |
SYSMHC00005_HCC1143 |
SYSMHC00005_20120321_EXQ1_MiBa_SA_HCC1143_1.raw |
Human |
In vitro |
Breast |
Hcc1143 |
adherent |
|
Basal like breast cancer |
class I |
HLA-A31:01,HLA-B35:08,HLA-B37:01,HLA-C04:01,HLA-C06:02 |
25576301 |
native |
Immunoaffinity |
W6/32 |
Q-Exactive |
nanoflow HPLC (Proxeon Biosystems, Thermo Fisher Scientific, Bremen, Germany) |
no |
DDA |
HCD |
2-30% ACN |
90 |
75μm id 2 cm |
1 |
| SYSMHC00005 |
SYSMHC00005_HCC1143 |
SYSMHC00005_20120321_EXQ1_MiBa_SA_HCC1143_2.raw |
Human |
In vitro |
Breast |
Hcc1143 |
adherent |
|
Basal like breast cancer |
class I |
HLA-A31:01,HLA-B35:08,HLA-B37:01,HLA-C04:01,HLA-C06:02 |
25576301 |
native |
Immunoaffinity |
W6/32 |
Q-Exactive |
nanoflow HPLC (Proxeon Biosystems, Thermo Fisher Scientific, Bremen, Germany) |
no |
DDA |
HCD |
2-30% ACN |
90 |
75μm id 2 cm |
2 |
| SYSMHC00005 |
SYSMHC00005_HCC1143 |
SYSMHC00005_20120322_EXQ1_MiBa_SA_HCC1143_1_A.raw |
Human |
In vitro |
Breast |
Hcc1143 |
adherent |
|
Basal like breast cancer |
class I |
HLA-A31:01,HLA-B35:08,HLA-B37:01,HLA-C04:01,HLA-C06:02 |
25576301 |
native |
Immunoaffinity |
W6/32 |
Q-Exactive |
nanoflow HPLC (Proxeon Biosystems, Thermo Fisher Scientific, Bremen, Germany) |
no |
DDA |
HCD |
2-30% ACN |
90 |
75μm id 2 cm |
3 |